BU-32: a novel proteasome inhibitor for breast cancer
نویسندگان
چکیده
منابع مشابه
Wedelolactone Acts as Proteasome Inhibitor in Breast Cancer Cells
Wedelolactone is a multi-target natural plant coumestan exhibiting cytotoxicity towards cancer cells. Although several molecular targets of wedelolactone have been recognized, the molecular mechanism of its cytotoxicity has not yet been elucidated. In this study, we show that wedelolactone acts as an inhibitor of chymotrypsin-like, trypsin-like, and caspase-like activities of proteasome in brea...
متن کاملA Novel Biocompatible Nanoprobe Based on Lipoproteins for Breast Cancer Cell Imaging
Objective(s): Contrast-enhanced magnetic resonance imaging (MRI) of breast cancer provides valuable data on the disease state of patients. Biocompatible nanoprobes are expected to play a pivotal role in medical diagnosis in the future owing to their prominent advantages. The present study aimed to introduce a novel biocompatible nanoprobe based on lipoproteins for breast cancer cell imaging.<br...
متن کاملSynthesis and Characterization of a Novel Niosome System Containing Adiantum Capillus-Veneris for Breast Cancer Therapy
Background: Due to the increase in cancer and side effects of common therapies, researchers are looking for treatments with the least side effects, which is why medicinal plants have become so important. Adiantum capillus-veneris L. plant commonly called southern maidenhair fern, and also named as “Pare-siavashan” in medical and pharmaceutical textbooks of Iranian Traditional Medicine, contains...
متن کاملA Novel RNA Helicase Inhibitor to Treat Breast Cancer
The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. Public reporting burden for this c ollection of information is esti mated to average 1 hour per res ponse, including the time for reviewing instruc tions, searching exis...
متن کاملA proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes.
PURPOSE The incidence of bone metastasis in advanced breast cancer (BrCa) exceeds 70%. Bortezomib, a proteasome inhibitor used for the treatment of multiple myeloma, also promotes bone formation. We tested the hypothesis that proteasome inhibitors can ameliorate BrCa osteolytic disease. EXPERIMENTAL DESIGN To address the potentially beneficial effect of bortezomib in reducing tumor growth in ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Breast Cancer Research
سال: 2009
ISSN: 1465-542X
DOI: 10.1186/bcr2411